Fig. 1 · Structure

Documents & Downloads

GO6983

Cat. No. A13790 CAS 133053-19-7

PKC inhibitor

GO6983 is a potent protein kinase C (PKC) inhibitor. It reduces polymorphonuclear leukocyte adherence and infiltration following myocardial ischemia/reperfusion injury.

In Stock

Publications for GO6983

1 publication citing this product

  1. Kouki Kawakami, .et al. , Nat Commun, 2022, 13: 487 PMID: 35078997

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

GO6983 inhibits multiple PKC isoforms in biochemical assays. In a recombinant kinase screen at 0.5 µM compound and 10 µM ATP, PKCα and PKCδ retained little activity, whereas PKCγ, PKCζ and PKCμ/PRKD1 retained appreciable activity. GSK3α and RSK1–4 were also inhibited, limiting attribution of GO6983 responses to PKC alone. These are single-concentration activity measurements. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PKCγ IC50 6nM
PKCα IC50 7nM
PKCβ IC50 7nM
PKCδ IC50 10nM
PKCζ IC50 60nM
PKCμ IC50 20μM

6 targets · Scroll to view more

In Vitro Studies

In AT1R-expressing HEK293 cells, Figure 3d shows a lower Ang II-associated ERK phosphorylation response with 3 µM Go6983, while a substantial response remains after 30 minutes of ligand stimulation. The response was nearly absent when Gq inhibition with YM-254890 accompanied Go6983. The remaining signal limits interpretation of Go6983 as a complete blocker of this cellular response. [2]

Recombinant kinase activity profile of Gö 6983

Biochemical assay · Recombinant human kinase panel; selected PKC/PKD, GSK3 and RSK measurements from a 300-kinase screen [1]

One coherent single-concentration kinase-panel experiment. PKC inhibition varied across isoforms, and several non-PKC kinases were inhibited at the same concentration. Values are mean percent activity remaining, not IC50 values. Weaker PKCγ/PKCζ/PKCμ responses and non-PKC effects are retained. The authors caution that 10 µM ATP, truncated constructs and incomplete kinome coverage limit extrapolation to cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PKCa substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 3.141353019186526% (mean of two replicates; spreadsheet value)[1]
PKCb1 substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 19.289364906301323% (mean of two replicates; spreadsheet value)[1]
PKCb2 substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 14.245029883712608% (mean of two replicates; spreadsheet value)[1]
PKCd substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 1.6733338474784611% (mean of two replicates; spreadsheet value)[1]
PKCepsilon substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 14.641380712434398% (mean of two replicates; spreadsheet value)[1]
PKCeta substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 6.845200277108306% (mean of two replicates; spreadsheet value)[1]
PKCg substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 54.020246583639526% (mean of two replicates; spreadsheet value)[1]
PKCiota substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 67.62486156425798% (mean of two replicates; spreadsheet value)[1]
PKCmu/PRKD1 substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 68.84923136369665% (mean of two replicates; spreadsheet value)[1]
PKCnu/PRKD3 substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 91.9319947451007% (mean of two replicates; spreadsheet value)[1]
PKCtheta substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 4.500038258806724% (mean of two replicates; spreadsheet value)[1]
PKCzeta substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 78.22843922361025% (mean of two replicates; spreadsheet value)[1]
PKD2/PRKD2 substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 92.29379875240141% (mean of two replicates; spreadsheet value)[1]
GSK3a substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 14.042058290843638% (mean of two replicates; spreadsheet value)[1]
GSK3b substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 31.977321635299703% (mean of two replicates; spreadsheet value)[1]
RSK1 substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 15.987054177267057% (mean of two replicates; spreadsheet value)[1]
RSK2 substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 6.550063057159029% (mean of two replicates; spreadsheet value)[1]
RSK3 substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 5.457282901495947% (mean of two replicates; spreadsheet value)[1]
RSK4 substrate-phosphorylation activity remaining relative to solvent controlremaining kinase activity (%) 4.524780576648927% (mean of two replicates; spreadsheet value)[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 µM Gö 6983; 10 µM ATP
Exposure duration
Approximately 20 min before ATP addition, followed by 120 min reaction at room temperature
Method
Radiometric substrate-phosphorylation HotSpot assay
Vehicle
1% DMSO in reaction buffer; results normalized to DMSO control
Reported limits
Kinase-specific substrates/construct boundaries in Supplementary Table 2 were not extracted. The source reports average compound-library purity >98%, which is not a GO6983-specific certificate.
Methods and source locations

Compound reported in the paper: Gö 6983; Compound label in the paper: Gö 6983; CAS 133053-19-7 in Supplementary Table 3

Compound-level biochemical evidence; no Adooq lot equivalence or cellular potency assumption.

Supplementary Table 3, Gö 6983 column BM; headers BM2–BM3; selected kinase rows; Results, A kinase-inhibitor interaction map; Methods, Kinase assays

PKCa substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, PKCa row 224, Gö 6983 cell BM224; table header; Methods, Kinase assays

PKCb1 substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, PKCb1 row 225, Gö 6983 cell BM225; table header; Methods, Kinase assays

PKCb2 substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, PKCb2 row 226, Gö 6983 cell BM226; table header; Methods, Kinase assays

PKCd substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, PKCd row 227, Gö 6983 cell BM227; table header; Methods, Kinase assays

PKCepsilon substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, PKCepsilon row 228, Gö 6983 cell BM228; table header; Methods, Kinase assays

PKCeta substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, PKCeta row 229, Gö 6983 cell BM229; table header; Methods, Kinase assays

PKCg substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, PKCg row 230, Gö 6983 cell BM230; table header; Methods, Kinase assays

PKCiota substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, PKCiota row 231, Gö 6983 cell BM231; table header; Methods, Kinase assays

PKCmu/PRKD1 substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, PKCmu/PRKD1 row 232, Gö 6983 cell BM232; table header; Methods, Kinase assays

PKCnu/PRKD3 substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, PKCnu/PRKD3 row 233, Gö 6983 cell BM233; table header; Methods, Kinase assays

PKCtheta substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, PKCtheta row 234, Gö 6983 cell BM234; table header; Methods, Kinase assays

PKCzeta substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, PKCzeta row 235, Gö 6983 cell BM235; table header; Methods, Kinase assays

PKD2/PRKD2 substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, PKD2/PRKD2 row 236, Gö 6983 cell BM236; table header; Methods, Kinase assays

GSK3a substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, GSK3a row 124, Gö 6983 cell BM124; table header; Methods, Kinase assays

GSK3b substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, GSK3b row 125, Gö 6983 cell BM125; table header; Methods, Kinase assays

RSK1 substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, RSK1 row 255, Gö 6983 cell BM255; table header; Methods, Kinase assays

RSK2 substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, RSK2 row 256, Gö 6983 cell BM256; table header; Methods, Kinase assays

RSK3 substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, RSK3 row 257, Gö 6983 cell BM257; table header; Methods, Kinase assays

RSK4 substrate-phosphorylation activity remaining relative to solvent control: HotSpot radiometric kinase activity assay; 0.5 µM Gö 6983, 10 µM ATP; inactive-enzyme background subtraction and normalization to DMSO control. — Supplementary Table 3, RSK4 row 258, Gö 6983 cell BM258; table header; Methods, Kinase assays

Go6983 and Gq inhibition in AT1R-dependent ERK phosphorylation

Cell-based study · AT1R-expressing parental HEK293 cells; AlphaLISA ERK1/2 phosphorylation assay [2]

Fig. 3d compares Ang II without Go6983, Ang II with Go6983, Ang II plus YM-254890 with Go6983, and TRV027 with Go6983. The Go6983-treated Ang II response remains substantial; adding Gq inhibition leaves little response. No cellular IC50 or exact fold changes are extracted. The caption reports mean ± SEM of three independent experiments, each performed in duplicate.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ERK activation (fold over basal), 30 min after ligand stimulationqualitative comparison of plotted response Lower Ang II response with Go6983 than without; residual Ang II response persists. Ang II + YM-254890 and TRV027 responses with Go6983 are near basal.[2]

Literature-Reported Treatment Conditions

Treatment concentration
Go6983 3 µM
Exposure duration
Ligand stimulation 30 min after Go6983 pretreatment; pretreatment interval not specified in the checked ERK assay section/caption
Method
Cell pretreatment followed by ligand stimulation, lysis and AlphaLISA analysis
Co-treatment
Ang II; comparison conditions include Ang II + YM-254890 and TRV027, each with Go6983
Reported limits
The checked Fig. 3d caption/ERK-method section does not specify ligand concentrations, Go6983 solvent or pretreatment interval. Imaging-specific 15-min pretreatment was not transferred to this assay.
Methods and source locations

Compound reported in the paper: Go6983; Compound label in the paper: Go6983 (Adooq)

Cellular pathway experiment under the reported conditions; no isoform-specific or complete ERK-blockade claim.

Fig. 3d and caption; Results, ERK phosphorylation paragraph; Methods, AlphaLISA-based ERK1/2 phosphorylation assay; Reagents and plasmids

ERK activation (fold over basal), 30 min after ligand stimulation: AlphaLISA ERK1/2 phosphorylation measurement; serum-starved AT1R-transfected HEK293 cells; mean ± SEM, 3 independent experiments, each in duplicate. — Fig. 3d (viewed) and caption; Methods, AlphaLISA-based ERK1/2 phosphorylation assay

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 133053-19-7
Applications PKC inhibitor
Formula C26H26N4O3
Molecular Weight 442.51
SMILES
CN(C)CCCN1C=C(C2=C1C=CC(=C2)OC)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 55 mg/mL (124.29 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% PEG400+0.5% Tween80+5% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Anastassiadis T, Deacon SW, Devarajan K, et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nature biotechnology (2011). PMID: 22037377 DOI: 10.1038/nbt.2017 Source material
  2. [2] Kawakami K, Yanagawa M, Hiratsuka S, et al. Heterotrimeric Gq proteins act as a switch for GRK5/6 selectivity underlying β-arrestin transducer bias. Nature communications (2022). PMID: 35078997 DOI: 10.1038/s41467-022-28056-7 Source material

Publications

1 publication citing this product

  1. Kouki Kawakami, .et al. , Nat Commun, 2022, 13: 487 PMID: 35078997

Added to your cart

View Cart Checkout
Loading...